# Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

> **NCT06956235** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 147 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Tulisokibart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06956235
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2026-11-16
- **Final completion:** 2029-01-22
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06956235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06956235, "Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06956235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*